What is DSIP?

Compound Spotlight

DSIP is one of the oldest compounds in this catalog and, nearly fifty years after its discovery, one of the least resolved. It has a name that states a function it has never reliably demonstrated, and no confirmed receptor. That combination makes it a genuinely interesting case study in how peptide research can stall.

How it was found

In 1977, Schoenenberger and Monnier reported isolating a peptide from the cerebral venous blood of rabbits in which sleep had been induced by electrical stimulation of the thalamus. The reasoning was that whatever circulating factor accompanied delta-wave sleep might itself be a sleep-inducing signal. They named what they found accordingly.

The sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — nine amino acids, no unusual residues, no complex structure. It is a small and chemically unremarkable molecule.

The naming turned out to be consequential. “Delta Sleep-Inducing Peptide” asserts a mechanism in the name itself, and five decades of subsequent research have not consistently confirmed it. A compound named for a hypothesis carries that hypothesis into every discussion of it, whether or not the evidence followed.

The receptor problem

For most peptides in this catalog, the mechanism section describes which receptor the compound binds and what happens downstream. For DSIP, that section cannot be written, because no specific DSIP receptor has been identified despite decades of searching.

This matters more than it might seem. Without a known receptor, it is not possible to run the kind of knockout or antagonist experiments that establish causation, to develop selective analogs, to characterize dose-response in a principled way, or to distinguish direct effects from indirect downstream consequences. The absence of a receptor is not merely a gap in the literature — it is a structural obstacle that has limited what any subsequent research could establish.

Proposed explanations include action through multiple low-affinity interactions rather than a single high-affinity receptor, or activity as a precursor or modulator rather than a direct agonist. None has been established.

What the sleep research actually shows

Inconsistency. Some studies have reported changes in sleep architecture or reduced sleep latency; others have found no significant effect. The literature does not converge on a reliable, reproducible sleep effect in the way the compound’s name implies.

Several factors plausibly contribute. The original isolation was from a small volume of rabbit blood under a specific experimental manipulation, and the concentrations involved were extremely low. Peptide stability and delivery vary considerably across study designs. And sleep is a difficult endpoint to measure consistently, with polysomnographic outcomes and subjective reports frequently diverging. Whatever the reason, the honest summary is that the sleep evidence is mixed rather than supportive.

Where the research went instead

Because the sleep findings did not consolidate, DSIP research diversified. The most durable thread concerns the hypothalamic-pituitary-adrenal axis: DSIP has been studied for effects on corticotropin and cortisol regulation, positioning it as a candidate stress-response modulator rather than a hypnotic. Some researchers have argued this stress-axis interaction is the more defensible line of investigation.

Additional directions have included pain modulation, opioid withdrawal research — where several older clinical reports described reduced withdrawal severity — and general neuroendocrine signaling. The withdrawal literature is among the more intriguing, though it is largely older, small, and not replicated to modern standards.

One property that is reasonably well supported: DSIP appears able to cross the blood-brain barrier, which is uncommon for peptides of its type and is part of why interest in it has persisted despite the mechanistic ambiguity.

How to read the DSIP literature

Much of the DSIP corpus dates from the late 1970s through the 1990s, which means it predates current standards for trial registration, statistical power, and publication of null results. Studies tend to be small. Publication bias plausibly favors positive findings. And because there is no receptor assay, target engagement is rarely confirmed — studies generally measure an outcome without establishing that the compound did what was assumed at the molecular level.

None of this makes the compound uninteresting. It does mean claims about DSIP should be read as hypotheses with partial support rather than established findings, and the confident phrasing common in commercial descriptions is not warranted by the underlying literature.

Frequently asked questions

Does DSIP reliably induce sleep?

The published evidence is inconsistent. Some studies report effects on sleep parameters and others find none. Despite the name, a reliable sleep-inducing effect is not established in the literature.

Why does the missing receptor matter?

Without an identified receptor, researchers cannot confirm target engagement, run antagonist or knockout experiments to establish causation, or design selective analogs. It limits what any study of the compound can conclusively demonstrate.

Is DSIP naturally present in humans?

DSIP-like immunoreactivity has been reported in human tissue and fluids, but the physiological role of the endogenous material is not well characterized, and detection methods across the older literature vary in specificity.

How do I know what is actually in the vial?

Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.

References

• Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram-sleep-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282–1286.
• Graf MV, Kastin AJ. Delta sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83–93.
• Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303–309.

View the DSIP product listing →

Look up your lot Certificate of Analysis →

For laboratory and research use only. Not for human consumption. DSIP is not approved by any regulatory authority. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.

Related research compounds

Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:

• DSIP

For laboratory research use only. Not for human consumption.